Applied Therapeutics, a Phase 2 biotech developing therapies for diabetic complications, raised $40 million by offering 4 million shares at $10, well below the range of $14 to $16. Applied Therapeutics plans to list on the Nasdaq under the symbol APLT. Citi, Cowen and UBS Investment Bank acted as lead managers on the deal.

The article Diabetic cardiomyopathy biotech Applied Therapeutics prices IPO at $10, well below the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of NASDAQ, Inc.